Authors: Yamano, K Yamamoto, K Katashima, M Kotaki, H Takedomi, S Matsuo, H Ohtani, H Sawada, Y Iga, T

Citation: K. Yamano et al., Prediction of midazolam-CYP3A inhibitors interaction in the human liver from in vivo/in vitro absorption, distribution, and metabolism data, DRUG META D, 29(4), 2001, pp. 443-452

Authors: Takedomi, S Matsuo, H Yamano, K Ohtani, H Sawada, Y

Citation: S. Takedomi et al., In-vivo kinetics of the interaction between midazolam and erythromycin in rats, taking account of metabolic intermediate complex formation, J PHARM PHA, 53(5), 2001, pp. 643-651

Authors: Yamano, K Yamamoto, K Kotaki, H Takedomi, S Matsuo, H Sawada, Y Iga, T

Citation: K. Yamano et al., Quantitative prediction of metabolic inhibition of midazolam by erythromycin, diltiazem, and verapamil in rats: Implication of concentrative uptake of inhibitors into liver, J PHARM EXP, 292(3), 2000, pp. 1118-1126

Authors: Yamano, K Yamamoto, K Kotaki, H Takedomi, S Matsuo, H Sawada, Y Iga, T

Citation: K. Yamano et al., Correlation between in vivo and in vitro hepatic uptake of metabolic inhibitors of cytochrome P-450 in rats, DRUG META D, 27(11), 1999, pp. 1225-1231